Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven chronic myelogenous leukemia
• * Must have (9;22) translocation or bcr/abl transcript, and b3a2 breakpoint
• * No accelerated or blastic phase
• Must be in hematologic remission with peripheral WBC less than 20,000/mm\^3
• PATIENT CHARACTERISTICS:
• Age:
• Over 16
• Performance status:
• Karnofsky 70-100%
• Life expectancy:
• Not specified
• Hematopoietic:
• See Disease Characteristics
• Absolute granulocyte count greater than 1,200/mm\^3
• Platelet count greater than 70,000/mm\^3
• Hemoglobin greater than 9.0 g/dL
• No active bleeding
• Hepatic:
• Bilirubin less than 2.0 mg/dL
• Lactate dehydrogenase less than 2 times normal
• Renal:
• Creatinine less than 2.0 mg/dL
• Cardiovascular:
• No New York Heart Association class III or IV heart disease
• Other:
• No uncontrolled active infection requiring antibiotics
• No other serious illness
• No immunodeficiency other than from prior bone marrow transplantation
• Not pregnant or nursing
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 6 months since prior allogeneic or autologous bone marrow transplantation
• Prior vaccination with pentavalent peptide at less than study dose level allowed
• At least 4 weeks since prior immunotherapy other than interferon, donor lymphocyte infusion, or pentavalent vaccine
• Concurrent interferon allowed
• Chemotherapy:
• At least 2 weeks since prior low-dose subcutaneous cytarabine
• At least 4 weeks since prior chemotherapy other than hydroxyurea
• No concurrent chemotherapy except hydroxyurea
• Endocrine therapy:
• No concurrent corticosteroids
• Radiotherapy:
• At least 4 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery:
• No concurrent surgery
• Other:
• Concurrent imatinib mesylate allowed
• No other concurrent systemic therapy